相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Immunogenic-cell-killing and immunosuppression-inhibiting nanomedicine
Ying Wang et al.
BIOACTIVE MATERIALS (2021)
Natural Killer Cells: Diverse Functions in Tumor Immunity and Defects in Pre-neoplastic and Neoplastic Stages of Tumorigenesis
Anahid Jewett et al.
MOLECULAR THERAPY-ONCOLYTICS (2020)
Poly(cyclodextrin)-Polydrug Nanocomplexes as Synthetic Oncolytic Virus for Locoregional Melanoma Chemoimmunotherapy
Jihoon Kim et al.
ADVANCED FUNCTIONAL MATERIALS (2020)
Codelivery of Anti-PD-1 Antibody and Paclitaxel with Matrix Metalloproteinase and pH Dual-Sensitive Micelles for Enhanced Tumor Chemoimmunotherapy
Zhenwei Su et al.
SMALL (2020)
Reshaping Tumor Immune Microenvironment through Acidity-Responsive Nanoparticles Featured with CRISPR/Cas9-Mediated Programmed Death-Ligand 1 Attenuation and Chemotherapeutics-Induced Immunogenic Cell Death
Kun Tu et al.
ACS APPLIED MATERIALS & INTERFACES (2020)
Paclitaxel Induces Immunogenic Cell Death in Ovarian Cancer via TLR4/IKK2/SNARE-Dependent Exocytosis
Tat San Lau et al.
CANCER IMMUNOLOGY RESEARCH (2020)
Nanomedicine-based drug delivery towards tumor biological and immunological microenvironment
Jin Li et al.
ACTA PHARMACEUTICA SINICA B (2020)
Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy
Qianmei Yang et al.
THERANOSTICS (2020)
Progress in research on paclitaxel and tumor immunotherapy
Linyan Zhu et al.
CELLULAR & MOLECULAR BIOLOGY LETTERS (2019)
Recent progress in drug delivery
Chong Li et al.
ACTA PHARMACEUTICA SINICA B (2019)
Antitumor activity of the bioreductive prodrug 3-(2-nitrophenyl) propionic acid-paclitaxel nanoparticles (NPPA-PTX NPs) on MDA-MB-231 cells: in vitro and in vivo
Xiao-Chuan Duan et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2019)
Enhanced Tumor Retention Effect by Click Chemistry for Improved Cancer Immunochemotherapy
Ling Mei et al.
ACS APPLIED MATERIALS & INTERFACES (2018)
Immunochemotherapy mediated by thermosponge nanoparticles for synergistic anti-tumor effects
Yongdan Zhao et al.
JOURNAL OF CONTROLLED RELEASE (2018)
Entry of nanoparticles into cells: the importance of nanoparticle properties
Jiacheng Zhao et al.
POLYMER CHEMISTRY (2018)
In situ formed reactive oxygen species-responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy
Chao Wang et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Binary Cooperative Prodrug Nanoparticles Improve Immunotherapy by Synergistically Modulating Immune Tumor Microenvironment
Bing Feng et al.
ADVANCED MATERIALS (2018)
Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies
Qiang Wang et al.
CANCER LETTERS (2018)
Nanoparticle-Mediated Remodeling of the Tumor Microenvironment to Enhance Immunotherapy
Sara Musetti et al.
ACS NANO (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)
Solange Peters et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
An Immunogram Immunogram for the Cancer-Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer
Takahiro Karasaki et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
J. Bellmunt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus)
Glen J. Weiss et al.
BRITISH JOURNAL OF CANCER (2017)
Immunogenic cell death in cancer and infectious disease
Lorenzo Galluzzi et al.
NATURE REVIEWS IMMUNOLOGY (2017)
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
Naiyer A. Rizvi et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?
F. Danhier
JOURNAL OF CONTROLLED RELEASE (2016)
Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM
Dimitrios Mathios et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
The anti-tumor efficacy of 3-(2-Nitrophenyl) propionic acid-paclitaxel (NPPA-PTX): a novel paclitaxel bioreductive prodrug
Ping Song et al.
ONCOTARGET (2016)
Prodrug Strategies for Paclitaxel
Ziyuan Meng et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer
Jin Peng et al.
CANCER RESEARCH (2015)
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
Padmanee Sharma et al.
CELL (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Yoshinari Asaoka et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Immune evasion in cancer: Mechanistic basis and therapeutic strategies
Dass S. Vinay et al.
SEMINARS IN CANCER BIOLOGY (2015)
The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
Leisha A. Emens et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8
A. Q. Sukkurwala et al.
CELL DEATH AND DIFFERENTIATION (2014)
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Thomas Powles et al.
NATURE (2014)
The transport pathways of polymer nanoparticles in MDCK epithelial cells
Bing He et al.
BIOMATERIALS (2013)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Immunogenic cell death and DAMPs in cancer therapy
Dmitri V. Krysko et al.
NATURE REVIEWS CANCER (2012)
Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy
Oliver Kepp et al.
CANCER AND METASTASIS REVIEWS (2011)
Cyclophosphamide Synergizes with Type I Interferons through Systemic Dendritic Cell Reactivation and Induction of Immunogenic Tumor Apoptosis
Giovanna Schiavoni et al.
CANCER RESEARCH (2011)
Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress
I. Martins et al.
ONCOGENE (2011)
HMGB1 and RAGE in Inflammation and Cancer
Gary P. Sims et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 28 (2010)
Immunogenic death of colon cancer cells treated with oxaliplatin
A. Tesniere et al.
ONCOGENE (2010)
Determinants for in vivo anti-tumor effects of PEG liposomal doxorubicin: Importance of vascular permeability within tumors
Ken-ichi Ogawara et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2008)
Effects of sustained and intermittent paclitaxel therapy on tumor repopulation in ovarian cancer
Vessela Vassileva et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Immunological aspects of cancer chemotherapy
Laurence Zitvogel et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
Lionel Apetoh et al.
NATURE MEDICINE (2007)
Calreticulin exposure dictates the immunogenicity of cancer cell death
Michel Obeid et al.
NATURE MEDICINE (2007)
Cancer immunoediting: from immunosurveillance to tumor escape
GP Dunn et al.
NATURE IMMUNOLOGY (2002)
Drug targeting
VP Torchilin
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2000)
分享论文
